Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptors 2 & 3 (mGlu2/3) for the Treatment of Depression
代谢型谷氨酸受体 2 的负变构调节剂 (NAM)
基本信息
- 批准号:10183332
- 负责人:
- 金额:$ 44.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-05 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AMPA ReceptorsAcidsAcuteAdultAffectAnestheticsAnhedoniaAnimal ExperimentsAntidepressive AgentsBehavioralBehavioral ModelBrainBrain-Derived Neurotrophic FactorChemosensitizationClinicalDataDiseaseDoseElectrophysiology (science)FRAP1 geneFailureFluoxetineFutureGlutamatesHabenulaHippocampus (Brain)HourHumanInjectionsIntravenousInvestigational DrugsKetamineLeadLearningMajor Depressive DisorderMeasurementMeasuresMedialMediatingMedicalMental DepressionMetabotropic Glutamate ReceptorsMicrodialysisModelingMolecularMotivationN-Methyl-D-Aspartate ReceptorsNeurobiologyNeuronsNorepinephrineOralPatientsPharmaceutical PreparationsPharmacologyPhasePlasmaPlayPrefrontal CortexProceduresPropertyProsencephalonRattusRewardsRodentRodent ModelRoleSafetySedation procedureSelective Serotonin Reuptake InhibitorSerotoninSmall Business Technology Transfer ResearchStructureSynapsesTherapeuticTreatment EfficacyTricyclic Antidepressive Agentsanalogantidepressant effectbrain tissuedepression modeldorsal raphe nucleusdrug candidateforced swim testglutamatergic signalingimprovedin vivoinhibitor/antagonistmetabotropic glutamate receptor 2motivated behaviornovelnovel drug classpreclinical developmentprogramsreceptorrelease factorresearch clinical testingreuptakeside effectsmall moleculestandard of caretreatment-resistant depression
项目摘要
SUMMARY
Treatment-resistant depression (TRD) affects 20-30% of major depressive disorder (MDD) patients and is
defined as a failure to respond to at least two adequate rounds of treatment with standard of care
antidepressants. TRD represents a substantial unmet medical need, requiring novel treatments with rapid and
sustained antidepressant activity and good safety and tolerability profiles. (S)-Ketamine (Spravato, Esketamine)
was recently approved for the treatment of TRD; however, it has several adverse side effects including sedation,
dissociative effects, and abuse liability. The precise mechanism of action (MOA) of ketamine remains unclear;
while described as a noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist, it has additional non-
NMDAR effects. In humans, ketamine is rapidly metabolized and some metabolites, such as (2R,6R)-
hydroxynorketamine (HNK), have rapid antidepressant-like activity in rodent models. The antidepressant-like
activity of HNK is partially mediated through metabotropic glutamate receptor subtype 2 (mGlu2). Thus, we
propose that negative allosteric modulation of mGlu2/3 represents a promising new strategy to treat TRD. Our
rationale is four-fold: (1) mGlu2/3 receptors are expressed in the forebrain regions affected in depression, with
particular enrichment in the medial prefrontal cortex, hippocampus and medial habenula, (2) inhibition of mGlu2/3
leads to molecular and cellular changes similar to those caused by ketamine, including α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor potentiation, brain-derived neurotrophic factor (BDNF)
release, activation of mammalian target of rapamycin (mTOR) and ultimately synaptic remodeling, (3) mGlu2/3
orthosteric antagonists produce ketamine-like behavioral effects with sustained efficacy in multiple rodent
procedures that model aspects of depression, and (4) the antidepressant-like activity of the ketamine metabolite
(2R,6R)-HNK in rodent models is partially mediated by mGlu2. Thus, mGlu2/3 negative allosteric modulators
(NAMs) are predicted to produce antidepressant effects similar to ketamine without the psychotomimetic side
effects. Our objective is to advance a mGlu2/3 NAM into preclinical development and IND-enabling studies. To
this end, we have identified a lead and a backup mGlu2/3 NAM with excellent drug-like properties. The specific
aims are the following: (1) Determine the efficacy of our lead mGlu2/3 NAM in the rodent Probabilistic Reward
Task (PRT) and Effort-related Choice (ERC) task after acute oral dosing; and (2) Determine target engagement
of our lead mGlu2/3 NAM in vivo. On completion of this Phase I STTR, we will be able to determine if the lead
compound and/or the backup have the efficacy and pharmacological profile to be advanced into preclinical
development, which would become the basis of a Phase II application. Hence, the studies proposed here are
important precedents to support a future clinical program for MDD and TRD.
摘要
难治性抑郁症(TRD)影响20%-30%的严重抑郁障碍(MDD)患者和IS
被定义为未能对至少两轮适当的治疗做出反应,并符合护理标准
抗抑郁药。TRD代表着大量未得到满足的医疗需求,需要使用快速和
持续的抗抑郁活性和良好的安全性和耐受性。(S)-氯胺酮(西班牙、埃斯氯胺酮)
最近被批准用于治疗TRD;然而,它有几个副作用,包括镇静,
分离效果和滥用责任。氯胺酮的确切作用机制(MOA)尚不清楚;
虽然被描述为非竞争性N-甲基-D-天冬氨酸受体(NMDAR)拮抗剂,但它具有额外的非
NMDAR效果。在人体内,氯胺酮代谢迅速,一些代谢物,如(2R,6R)-
羟基去甲氯胺酮(HNK)在啮齿动物模型中具有快速的抗抑郁药样活性。类抗抑郁药
HNK的活性部分通过代谢型谷氨酸受体亚型2(MGlu2)介导。因此,我们
提出mGlu2/3的负变构调节是治疗TRD的一种有前景的新策略。我们的
理由有四个:(1)mGlu2/3受体在抑郁症患者的前脑区域表达,
内侧前额叶皮质、海马和内侧缰核的特别丰富,(2)mGlu2/3的抑制
导致类似于氯胺酮引起的分子和细胞变化,包括α-氨基-3-羟基-5-
甲基-4-异恶唑丙酸(AMPA)受体增强,脑源性神经营养因子
哺乳动物雷帕霉素靶标(MTOR)的释放、激活和最终突触重构,(3)mGlu2/3
正构体拮抗剂在多只啮齿动物身上产生持续有效的氯胺酮样行为效应
模拟抑郁症各方面的程序,以及(4)氯胺酮代谢物的抗抑郁药样活性
啮齿动物模型中的(2R,6R)-HNK部分由mGlu2介导。因此,mGlu2/3负变构调节剂
(NAM)被预测产生类似于氯胺酮的抗抑郁作用,而没有精神分裂的一面
效果。我们的目标是推动mGlu2/3NAM进入临床前开发和IND使能研究。至
为此,我们确定了具有良好类药物特性的先导和备用mGlu2/3 NAM。具体的
目的如下:(1)确定我们的先导mGlu2/3NAM在啮齿动物概率奖赏中的有效性
急性口服给药后的任务(PRT)和努力相关选择(ERC)任务;以及(2)确定目标投入
我们的主要mGlu2/3NAM在体内。在完成此第一阶段STTR后,我们将能够确定Lead是否
化合物和/或制剂具有进入临床前阶段的疗效和药理作用
开发,这将成为第二阶段应用程序的基础。因此,这里提出的研究是
支持未来MDD和TRD临床计划的重要先例。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Reto Andreas Gadient其他文献
Reto Andreas Gadient的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Reto Andreas Gadient', 18)}}的其他基金
Preclinical validation of mGlu2 PAMs in alcohol use disorder
mGlu2 PAM 在酒精使用障碍中的临床前验证
- 批准号:
10815668 - 财政年份:2023
- 资助金额:
$ 44.95万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Gene expression regulation in recurrent paediatric acute myeloid leukaemia by characterization of non-coding ribonucleic acids
通过非编码核糖核酸的表征研究复发性小儿急性髓性白血病的基因表达调控
- 批准号:
449784 - 财政年份:2020
- 资助金额:
$ 44.95万 - 项目类别:
Studentship Programs
Study of metabolism of sulfur-containing amino acids as anti-oxidant against the acute exacerbation of interstitial pneumonia
含硫氨基酸抗氧化代谢对间质性肺炎急性加重的研究
- 批准号:
16K19984 - 财政年份:2016
- 资助金额:
$ 44.95万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Omega 3 Fatty Acids Acute Neuroprotection via Mitochondria
Omega 3 脂肪酸通过线粒体提供急性神经保护作用
- 批准号:
9450547 - 财政年份:2015
- 资助金额:
$ 44.95万 - 项目类别:
Omega 3 fatty acids, acute neuroprotection via mitochondria
Omega 3 脂肪酸,通过线粒体提供急性神经保护
- 批准号:
10447712 - 财政年份:2015
- 资助金额:
$ 44.95万 - 项目类别:
Omega 3 fatty acids, acute neuroprotection via mitochondria
Omega 3 脂肪酸,通过线粒体提供急性神经保护
- 批准号:
10297604 - 财政年份:2015
- 资助金额:
$ 44.95万 - 项目类别:
Omega 3 Fatty Acids, Acute Neuroprotection Via Mitochondria
Omega 3 脂肪酸,通过线粒体提供急性神经保护
- 批准号:
10655664 - 财政年份:2015
- 资助金额:
$ 44.95万 - 项目类别:
Omega 3 Fatty Acids Acute Neuroprotection via Mitochondria
Omega 3 脂肪酸通过线粒体提供急性神经保护作用
- 批准号:
8996605 - 财政年份:2015
- 资助金额:
$ 44.95万 - 项目类别:
ACUTE EFFECTS OF OLANZAPINE ON PLASMA LEPTIN, GLUCOSE TOLERANCE FREE FATTY ACIDS
奥氮平对血浆瘦素、无葡萄糖耐量脂肪酸的急性影响
- 批准号:
7951282 - 财政年份:2009
- 资助金额:
$ 44.95万 - 项目类别:
SENSITIVITY TO ACUTE INSULIN MEDIATED SUPPRESSION OF PLASMA FREE FATTY ACIDS
对胰岛素介导的血浆游离脂肪酸急性抑制的敏感性
- 批准号:
7180051 - 财政年份:2005
- 资助金额:
$ 44.95万 - 项目类别:
SENSITIVITY TO ACUTE INSULIN MEDIATED SUPPRESSION OF PLASMA FREE FATTY ACIDS
对胰岛素介导的血浆游离脂肪酸急性抑制的敏感性
- 批准号:
6977013 - 财政年份:2003
- 资助金额:
$ 44.95万 - 项目类别:














{{item.name}}会员




